-transparent.png){kind=logo}
BACKGROUND Changeover from Phadebas RAST to Pharmacia AutoCAP increased double-positivity to both honey-bee and common wasp (vespula) venom in our patients. OBJECTIVE We examined the frequency of IgE double-positivity, its clinical relevance and utility in investigating potentially allergic patients. METHODS One hundred and eighty-two patients with hymenoptera allergy were tested using RAST (n = 51) and AutoCAP (n = 131) assays over 4 years. Patients had a history of reactions to vespulae (22), honey-bee (10) and unidentified hymenoptera (vespinae) (7). RESULTS After changing from RAST to AutoCAP double-positivity increased from 10 (5/ 51) to 30% (39/131) (P < 0.01). RAST and CAP assays gave similar median class results (vespula = 3, honey-bee = 2). Thirty-six CAP patients had systemic reactions of Mueller grade II and above. In vespula-allergic double-positive subjects, high CAP classes (> or = class 3) to honey-bee were common (30%). In 25% the CAP classes were equal. In honey-bee-allergic subjects, all vespula venom CAP IgE was low titre (class 1 or 2) and 20% were equal for both venoms. In 43% of vespinae-allergic patients the CAP class was equal to both (class 2 and 3). In contrast, intradermal skin test double-positivity was uncommon. Double-negative skin test results were common in the CAP double-positive population (22% of honey-bee-allergic, 13% of vespula-allergic and 43% of vespinae-allergic patients). Vespula allergic patients have higher bee-venom IgE than vice versa. Twenty-seven per cent of CAP double-positive patients (representing 8% of all venom allergic patients tested over this period) had equal class IgE to both venoms which was not helpful in diagnosis. Combination of skin testing and CAP is unhelpful in only 5/37 (14%) of patients with double-positive serology. CONCLUSIONS If used in isolation CAP may be misleading, especially if only one venom is tested. Identification of the causative venom must utilize both clinical history and skin testing in these double-positive patients, and challenge testing if indicated.
W Egner, and
C Ward, and
D L Brown, and
P W Ewan
June 1993,
Nihon hoigaku zasshi = The Japanese journal of legal medicine,
W Egner, and
C Ward, and
D L Brown, and
P W Ewan
October 1981,
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
W Egner, and
C Ward, and
D L Brown, and
P W Ewan
May 1997,
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
W Egner, and
C Ward, and
D L Brown, and
P W Ewan
July 1972,
Science (New York, N.Y.),
W Egner, and
C Ward, and
D L Brown, and
P W Ewan
January 1982,
Toxicon : official journal of the International Society on Toxinology,
W Egner, and
C Ward, and
D L Brown, and
P W Ewan
February 1983,
Zeitschrift fur Hautkrankheiten,
W Egner, and
C Ward, and
D L Brown, and
P W Ewan
June 1986,
Nederlands tijdschrift voor geneeskunde,
W Egner, and
C Ward, and
D L Brown, and
P W Ewan
August 2019,
Iranian journal of public health,
W Egner, and
C Ward, and
D L Brown, and
P W Ewan
September 1985,
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
W Egner, and
C Ward, and
D L Brown, and
P W Ewan
September 1974,
Pharmazie in unserer Zeit,
